Peptigrade

Cosmetic & Skin

SNAP-8

Acetyl Octapeptide-3 — Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂·Also known as: Acetyl Octapeptide-3, Acetyl Octapeptide-1, Acetyl Glutamyl Heptapeptide-3, Acetyl Glutamyl Octapeptide-3, SNAP-8™

FDARegulatory status

Not approved as a therapeutic drug for any human indication. Permitted in the United States as a cosmetic ingredient under 21 CFR Part 701 when used in finished cosmetic products; cosmetic ingredient safety is the responsibility of the manufacturer, not FDA pre-market approval.

WADARegulatory status

Not listed by name on the 2026 WADA Prohibited List. Topical cosmetic use is not a doping concern; systemic/injectable use would fall under S0 (non-approved substances) by default given the absence of any regulatory approval for therapeutic use.

Regulatory note ·SNAP-8 is a synthetic octapeptide marketed under the SNAP-8™ trademark by Lipotec S.A. (a subsidiary of Lubrizol, a Berkshire Hathaway company) as a topical cosmetic ingredient positioned as an extended analog of Argireline (Acetyl Hexapeptide-8). It is not approved for human therapeutic use by FDA, EMA, or any major regulator. Published human efficacy data is limited; most circulated efficacy numbers (62% maximum / 35% mean wrinkle-depth reduction) trace to manufacturer marketing literature and a single 28-day study in 17 subjects on a 10% topical formulation. There is no independent RCT against vehicle for SNAP-8 as a single ingredient in the peer-reviewed literature as of 2026-04-20.

§ The quick take

TL;DR · Editor’s summary

SNAP-8 (Acetyl Octapeptide-3) is a topical cosmetic peptide marketed by Lipotec/Lubrizol as an extended, higher-potency analog of Argireline. Its proposed mechanism — competitive interference with SNAP-25 incorporation into the SNARE complex, reducing acetylcholine release at the neuromuscular junction and softening dynamic expression lines — is mechanistically plausible and supported by in vitro synaptosome data (roughly 43% inhibition of glutamate release at 1.5 mM in the Blanes-Mira-derived assay line). The honest read on human efficacy is thinner than the marketing suggests.

The headline numbers circulated in trade literature (62% maximum / 35% mean wrinkle-depth reduction; 30% greater activity than Argireline) originate in Lipotec-sponsored testing and a single 28-day trial in 17 healthy female volunteers using a 10% topical formulation, measured by laser scanning of silicone skin imprints rather than standardized dermatological endpoints. There is no independent, peer-reviewed, vehicle-controlled RCT of SNAP-8 as a single ingredient as of 2026-04-20. Independent cosmetic-peptide reviews (Errante 2020, Gorouhi 2009-era lineage updated through Ferreira 2024) consistently describe the effect as real but modest, and note that the molecule's high molecular weight (~1075 Da), hydrophilicity, and methionine-driven oxidation sensitivity make stratum-corneum penetration the rate-limiting problem — which is why most current research is about delivery vehicles (dissolving microneedles, liposomes) rather than the peptide itself.

SNAP-8 is not FDA-approved as a drug; it is regulated as a cosmetic ingredient. It is not a substitute for botulinum toxin and has never been tested against it in a controlled clinical setting. Injectable or systemic claims are not supported by any published human data.

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for SNAP-8, sorted by strength of evidence.

C

Fine-line / wrinkle depth reduction (topical)

Mixed

Manufacturer-sponsored 28-day study in 17 healthy female volunteers using a 10% topical formulation reported statistically significant reduction in wrinkle depth measured by laser scanning of silicone skin imprints (mean ~35%, maximum ~62% in the responder subset). No independent, peer-reviewed, vehicle-controlled RCT of SNAP-8 as a single ingredient has been published. Effect size in independent cosmetic-peptide reviews is consistently described as modest and dependent on formulation.

4 studiesUpdated 2026-04-20
C

SNARE-complex / glutamate-release inhibition (in vitro)

Mixed

In vitro synaptosome assays attributed to the Blanes-Mira 2002 SNAP-25 mimetic line report ~43% inhibition of glutamate release at 1.5 mM SNAP-8. Mechanism characterized as competitive disruption of SNARE ternary complex assembly rather than enzymatic cleavage. Cellular-assay evidence only; no human neuromuscular data.

3 studiesUpdated 2026-04-20
D

Comparative efficacy vs Argireline (Acetyl Hexapeptide-8)

Weak

Industry side-by-side testing (Lipotec technical documentation summarized in Errante 2020 review) reports SNAP-8 as ~30% more active than Argireline in in vitro assays, with ~35% vs ~28% wrinkle-depth reduction in parallel topical panels. No head-to-head peer-reviewed RCT exists; the comparison rests on manufacturer data.

2 studiesUpdated 2026-04-20
D

Transdermal delivery via dissolving microneedle patches

Weak

Formulation-science work (hyaluronic-acid dissolving microneedles loaded with SNAP-8, quantified by validated LC-MS/MS per Kim 2020) demonstrates improved in vitro skin permeation versus conventional creams. No human clinical efficacy trial of a microneedle-delivered SNAP-8 product has been published.

3 studiesUpdated 2026-04-20
D

Blepharospasm / involuntary muscle contraction (adjunctive topical)

Weak

Proof-of-concept comes from a 2016 pilot study of topical Acetyl Hexapeptide-8 (Argireline, not SNAP-8) as adjunct to botulinum toxin for blepharospasm. The SNAP-8 extrapolation is mechanistic only. No SNAP-8-specific clinical trial for this indication.

1 studiesUpdated 2026-04-20
Ins.

Injectable or systemic use

Insufficient

No peer-reviewed human pharmacokinetic, safety, or efficacy data for injectable SNAP-8. The molecule is developed and characterized exclusively as a topical cosmetic active. Any injectable use is off-indication and unsupported.

0 studiesUpdated 2026-04-20

§ Why this grade

Sub-scores for this outcome.

Fine-line / wrinkle depth reduction (topical)

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

3 / 5

SNARE-complex competitive inhibition is mechanistically plausible and supported by in vitro synaptosome data (glutamate-release inhibition ~43% at 1.5 mM, Blanes-Mira 2002 assay lineage). The link from cellular assay to clinical wrinkle-depth reduction is inferred, not demonstrated. No in vivo human neuromuscular-junction measurement exists. Secondary Synaptotagmin-1 interaction is hypothesis-stage.

Human studies (count + quality)

2 / 5

One 28-day manufacturer-sponsored study in 17 healthy female volunteers on a 10% topical formulation, measured by laser scanning of silicone skin imprints. No independent replication. No vehicle-controlled RCT of SNAP-8 as a single ingredient in peer-reviewed literature as of 2026-04-20.

Effect vs placebo

2 / 5

The 28-day study is not a peer-reviewed vehicle-controlled RCT. Independent cosmetic-peptide reviews describe the effect as modest and formulation-dependent. Without an independent placebo arm, effect-vs-placebo quality is low.

Long-term safety data

3 / 5

Decades of topical cosmetic exposure at 5–10% in finished products with no published signal of systemic adverse events. No published human study extends beyond ~90 days. No injectable safety data in humans.

Side effect profile

4 / 5

Topical tolerability is consistently reported as excellent in cosmetic-industry testing. The molecule's size and hydrophilicity that limit efficacy also limit systemic exposure, which is a safety advantage for topical use.

Regulatory status

2 / 5

Permitted as a cosmetic ingredient under existing cosmetic-ingredient frameworks; not evaluated or approved as a drug by FDA, EMA, or any major therapeutic regulator. Not listed by name on the 2026 WADA Prohibited List.

§ What the science says

How SNAP-8
works.

The scientific explanation of the molecule and its proposed mechanism, with a plain-English translation — written at an 8th-grade reading level — in the teal callouts below each section. Every claim is linked to a primary source below.

What it is

SNAP-8 is a synthetic acetylated octapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ (one-letter: Ac-EEMQRRAD-NH₂), molecular formula C₄₁H₇₀N₁₆O₁₆S, molecular weight 1075.16 Da, CAS 868844-74-0, PubChem CID 86080331. It is a biomimetic fragment of the N-terminal domain of SNAP-25 (Synaptosomal Associated Protein of 25 kDa), one of the three proteins that form the SNARE complex responsible for calcium-dependent neurotransmitter vesicle fusion at the neuromuscular junction. SNAP-8 was developed by Lipotec S.A. (Barcelona) as an elongated, two-amino-acid extension of Argireline (Acetyl Hexapeptide-8) and is marketed as SNAP-8™ for incorporation into topical anti-wrinkle cosmetics at typical use concentrations of 5–10%. Lipotec was acquired by Lubrizol in 2012; Lubrizol is a wholly owned subsidiary of Berkshire Hathaway.

In plain English

SNAP-8 is a synthetic 8-amino-acid peptide sold as a cosmetic ingredient by Lipotec (owned by Lubrizol, which is owned by Berkshire Hathaway). It was designed as an extended version of Argireline, with the same basic idea but two extra amino acids added. Both are modeled on a small piece of SNAP-25 — a protein that nerve endings use to release chemicals onto muscles. The theory: if this peptide fills in for part of SNAP-25, it partially disrupts that release, producing slightly weaker muscle contractions and shallower expression lines over time. At 1,075 Da (daltons), it is a relatively large cosmetic peptide. That size creates a delivery problem: the outer skin barrier (the stratum corneum) acts as a wall, and molecules over 500 Da generally have trouble crossing it. SNAP-8 is more than twice that size. Most research now focuses on how to push it past that barrier (dissolving microneedles, liposomes), not on the peptide itself. It is not approved as a drug anywhere in the world. It is only regulated as a cosmetic ingredient.

How it works

  1. 01

    Biomimetic SNAP-25 fragment — competitive SNARE disruption

    SNAP-8 is designed to mimic the N-terminal region of SNAP-25 and compete with native SNAP-25 for assembly into the ternary SNARE complex (SNAP-25 + Syntaxin-1 + VAMP/synaptobrevin). Destabilizing ternary-complex formation reduces — but does not abolish — calcium-triggered vesicle fusion and acetylcholine release at the motor endplate. This is the mechanistic line established for SNAP-25-mimetic peptides in the Blanes-Mira 2002 work on which the Argireline/SNAP-8 family is built, and summarized in the 2020 Errante cosmeceutical-peptide review.

    In plain English

    It competes with a nerve-signaling protein to weaken muscle contractions

    Inside nerve endings, three proteins (SNAP-25, Syntaxin-1, and VAMP) zip together to form a complex that pulls chemical-release vesicles to the nerve membrane. SNAP-8 is shaped like a piece of SNAP-25. It competes for the same slot in that three-protein zipper. When enough SNAP-8 gets in the way, fewer vesicles complete the release — so the muscle signal is slightly weaker. This is a partial, reversible block, not a complete cut-off.

  2. 02

    In vitro neurotransmitter-release inhibition

    Synaptosome assays referenced in the Lipotec technical dossier and downstream reviews report ~43% inhibition of glutamate release at 1.5 mM SNAP-8, with concentration-dependent behavior. This is an in vitro neuronal-preparation endpoint, not a human neuromuscular measurement. The same assay line is cited for comparative activity claims versus Argireline.

    In plain English

    In lab-dish nerve preparations, it blocked about 43% of neurotransmitter release

    When applied at high concentration to isolated nerve preparations in lab dishes, SNAP-8 blocked about 43% of neurotransmitter release. The effect was dose-dependent. This is a cell-level measurement — not a measurement in human facial muscles. The same test is used to generate the comparison claims versus Argireline.

  3. 03

    Contrast with botulinum toxin A

    Botulinum toxin A is a zinc-dependent metalloprotease that enzymatically cleaves SNAP-25, producing complete, long-duration blockade of acetylcholine release and muscle paralysis lasting 3–6 months. SNAP-8 acts non-enzymatically and competitively; its effect is partial, dose-dependent, and reversible. This mechanistic contrast — highlighted in the Ferreira 2024 peptide-cosmeceutical review and the PMC12193160 2024 Acetyl-Hexapeptide-8 permeability review — is the basis for both its favorable topical safety profile and its substantially smaller clinical effect size.

    In plain English

    It is NOT Botox — the mechanism and effect size are very different

    Botox (botulinum toxin A) is an enzyme that permanently cuts SNAP-25, completely blocking chemical release and paralyzing the muscle for 3–6 months. SNAP-8 does not cut anything. It competes, partially, and reversibly. The effect is much smaller — but so are the side effects. A skin cream can't paralyze anything the way an injection can. This mechanistic difference explains both why SNAP-8 is safe as a cosmetic and why it can't replicate Botox results.

  4. 04

    Proposed secondary interaction with Synaptotagmin-1

    Review-level commentary (PMC10679740, Ferreira 2023 peptide–cell-surface interactions) hypothesizes that SNAP-8 may also bind the C2A–C2B interface of Synaptotagmin-1 and interfere with its calcium-sensing role in synchronized exocytosis. This is hypothesis-stage; no direct structural or biochemical characterization of a SNAP-8 / Syt1 interaction has been published.

    In plain English

    A theory says it may also interfere with the calcium sensor — unproven

    Some review papers suggest SNAP-8 might also interfere with Synaptotagmin-1 — the protein that detects calcium and triggers neurotransmitter release. If true, this would be a second way SNAP-8 reduces nerve signaling. But this is a hypothesis only. No experimental study has directly tested whether SNAP-8 actually binds or blocks Synaptotagmin-1.

  5. 05

    Permeability is the rate-limiting problem, not potency

    With MW ~1075 Da, strong hydrophilicity, and methionine-mediated oxidation sensitivity, SNAP-8 violates most small-molecule rules for stratum-corneum penetration (Bos & Meinardi 500-Da rule, updated in the PMC12193160 2024 permeability review). Independent cosmetic-chemistry analyses consistently identify delivery, not intrinsic activity, as the dominant determinant of clinical effect. This is why current research effort concentrates on vehicles — dissolving hyaluronic-acid microneedle patches (Kim 2020 LC-MS/MS method development), liposomal encapsulation, and penetration enhancers — rather than on the peptide itself.

    In plain English

    The real challenge is getting the peptide past the skin barrier

    At 1,075 Da, SNAP-8 is more than twice the size (500 Da) that can typically cross the outer skin layer. It also dissolves in water rather than fats — which doesn't help it get through the oily outer skin barrier. And the methionine amino acid in it can oxidize over time, reducing activity. Reviews consistently say delivery, not the peptide's potency, is the main limiting factor. That's why current research focuses on dissolving microneedle patches, liposomes, and penetration enhancers — not on changing the peptide itself.

  6. 06

    What is NOT known about the mechanism

    No in vivo human neuromuscular-junction measurement of SNAP-8 effect on acetylcholine release exists. The link from in vitro synaptosome glutamate-release inhibition to clinical reduction of facial expression lines is inferred, not demonstrated. Human pharmacokinetics (tissue concentration reached in dermal or subcutaneous compartments after topical application, persistence, clearance) are not characterized in peer-reviewed literature. No specific receptor has been identified because the mechanism is protein–protein-interaction–based rather than receptor-mediated.

    In plain English

    What we still don't know

    No one has published a human study measuring SNAP-8's effect on actual acetylcholine release at the neuromuscular junction. The jump from in vitro cell data to clinical wrinkle reduction is assumed, not demonstrated. We don't know how much SNAP-8 from a topical cream actually reaches the dermis or the nerve-muscle junction, how long it stays, or how it is cleared. There is no specific receptor to identify — the mechanism works through protein competition, not receptor binding.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • Topical reduction of dynamic facial wrinkles (expression lines)

    Manufacturer-sponsored 28-day study (n=17) on 10% topical formulation; multiple cosmetic-formulation reviews — Grade C

  • Comparative positioning vs Argireline (Acetyl Hexapeptide-8)

    Lipotec/Lubrizol technical comparison data; no independent head-to-head RCT — Grade D

  • Microneedle-delivered topical cosmetics

    Formulation and analytical-method development (Kim 2020) — no human efficacy trial published — Grade D

  • Combination topical cosmetic actives (with Leuphasyl, Matrixyl, hyaluronic acid)

    Industry synergy claims; no independent clinical trial isolating SNAP-8's contribution — Grade D

  • Blepharospasm and involuntary periorbital muscle contraction

    Mechanistic extrapolation from a 2016 Argireline pilot (PMC4747634); no SNAP-8-specific trial — Grade D

  • Injectable or systemic therapeutic use

    No peer-reviewed human data — Grade Insufficient

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    No independent, peer-reviewed, vehicle-controlled RCT of SNAP-8 as a single ingredient has been published. The widely cited 62% maximum and 35% mean wrinkle-depth figures originate in manufacturer-sponsored testing.

  • !

    No head-to-head peer-reviewed comparison of SNAP-8 against Argireline, against topical retinoids, or against any established anti-aging benchmark exists. The ~30% greater activity claim is based on in vitro assay output from the developer.

  • !

    Human pharmacokinetics after topical application (what concentration actually reaches the viable epidermis or dermis, how long it persists, how it is cleared) are not characterized in peer-reviewed literature.

  • !

    Skin penetration is the rate-limiting variable and has not been quantitatively established in a published human study for SNAP-8 specifically. A molecule of ~1075 Da is well above the conventional 500-Da stratum-corneum cutoff; how much of the labeled concentration is bioavailable at the target tissue is unknown.

  • !

    No long-term (>90-day) human tolerability or repeat-exposure safety study has been published for SNAP-8 as a single ingredient.

  • !

    The proposed secondary interaction with Synaptotagmin-1 is hypothesis-stage. No binding-affinity, co-crystallography, or functional-knockout data supports it.

  • !

    Oxidation behavior of the methionine residue in finished cosmetic matrices over realistic shelf-life is not publicly characterized, which matters because oxidized methionine is a known route to loss of peptide bioactivity.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing SNAP-8and tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • Peptides in Skincare — What Actually Works and What Doesn't

    Lab Muffin Beauty Science·PhD Chemistry

    Covers the Argireline / SNAP-8 family as plausible but modest. Explicitly notes that cosmetic-peptide efficacy claims typically rest on manufacturer data, not independent RCTs, and that stratum-corneum penetration is the limiting factor.

    Verified credentials

  • Argireline vs SNAP-8 vs Botox — An Honest Dermatologist Review

    Dr. Dray·MD, Board-Certified Dermatologist

    Describes SNAP-8 as a reasonable topical cosmetic ingredient with a real but small effect on fine lines, and is explicit that it is not a botulinum-toxin substitute and should not be marketed as one.

    Verified credentials

  • I Tried SNAP-8 Serum for 30 Days — Shocking Results!

    Anonymous skincare influencer·Unverified

    Before/after photos with no standardized lighting, no objective measurement, and no vehicle control. Illustrative of the anecdotal content that dominates search results for this ingredient. Do not weight against published evidence.

    Caution — anecdotal

§ Citations

Every claim,
linked to source.

All 12 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    Cosmeceutical peptides in the framework of sustainable wellness economy

    Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM · Frontiers in Chemistry · 2020

    Systematic reviewDOI
  2. [02]

    Acetyl hexapeptide-8 in cosmeceuticals — a review of skin permeability and efficacy

    Ferreira MS, Magalhães MC, Sousa-Lobo JM, Almeida IF · Cosmetics · 2024

    Systematic reviewDOI
  3. [03]

    Longitudinal analysis of public and scientific interest in acetyl hexapeptide-8

    Juhasz MLW, Mesinkovska NA, et al. · Archives of Dermatological Research · 2024

    CohortDOI
  4. [04]

    Pilot study of topical acetyl hexapeptide-8 in the treatment of blepharospasm as an adjunct to botulinum toxin

    Lovisolo F, De Rossi M, Dall'Occo MT, et al. · Dermatology Research and Practice · 2016

    PilotDOI
  5. [05]

    Current approaches in cosmeceuticals — peptides, biotics and marine biopolymers

    Pai VV, Bhandari P, Shukla P · Cosmetics · 2025

    Systematic reviewDOI
  6. [06]

    A randomized, double-blind, placebo-controlled clinical study investigating the efficacy and tolerability of a peptide serum targeting expression lines

    Farwick M, Grether-Beck S, Marini A, et al. · Journal of Clinical and Aesthetic Dermatology · 2021

    RCTDOI
  7. [07]

    Role of peptide–cell surface interactions in cosmetic peptide application

    Ferreira MS, Magalhães MC, Sousa-Lobo JM, Almeida IF · International Journal of Molecular Sciences · 2023

    Systematic reviewDOI
  8. [08]

    Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry and its application to biodegradable microneedle patches

    Kim YC, Park JH, Prausnitz MR, et al. · Journal of Analytical Science and Technology · 2020

    In vitroDOI
  9. [09]

    SNAP-8 (Acetyl Glutamyl Heptapeptide-3) — PubChem CID 86080331

    National Center for Biotechnology Information · PubChem · 2026

    RegulatoryLink
  10. [10]

    SNAP-8™ peptide solution C — technical product page

    Lubrizol Personal Care (Lipotec) · Lubrizol · 2024

    RegulatoryLink
  11. [11]

    FDA — Cosmetic ingredient safety and 21 CFR Part 701 labeling requirements

    U.S. Food and Drug Administration · FDA · 2026

    RegulatoryLink
  12. [12]

    WADA 2026 Prohibited List (in force January 1, 2026)

    World Anti-Doping Agency · WADA · 2026

    RegulatoryLink

§ Adjacent peptides

Worth reading
alongside this.

Compare

GHK-Cu

The other topical cosmetic peptide on Peptigrade with comparable regulatory framing — cosmetic ingredient, not a drug. Different mechanism (copper-binding tripeptide vs SNARE-complex mimic) but a similar evidence-quality story: real topical effects, overstated systemic claims.

Read its grades

Compare

BPC-157

Often stacked by consumers with cosmetic peptides in anti-aging regimens. Provides contrast: BPC-157 is an investigational therapeutic peptide (not a cosmetic ingredient) with extensive preclinical but thin human data, whereas SNAP-8 is a cosmetic ingredient with modest topical human data.

Read its grades

Compare

TB-500 (Thymosin β-4)

Another peptide frequently marketed with overstated regenerative claims. Useful comparator for how to distinguish a cosmetic-grade topical from an investigational systemic peptide when evaluating marketing copy.

Read its grades

Where to research further

Looking for SNAP-8
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →